Biosimilars Gaining Ground in Rheumatoid Arthritis

04-11-2013 MedscapeComments (0)


The biosimilar CT-P13 was comparable to infliximab in patients with rheumatoid arthritis for all disease-related and safety assessments in a 1-year extension of the PLANETRA study. "CT-P13 was effective and well tolerated over 2 years ...

Read more on Medscape

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top